https://www.nasdaq.com/press-release/aravive-announces-%2410.0-million-investment-by-eshelman-ventures-llc-and-appointment
https://www.nasdaq.com/press-release/aravive-to-participate-in-fireside-chat-at-piper-sandler-33rd-annual-virtual
https://www.nasdaq.com/press-release/aravive-announces-positive-preliminary-data-from-phase-1b-trial-evaluating-0
https://www.nasdaq.com/press-release/aravive-announces-positive-preliminary-data-from-phase-1b-trial-evaluating
https://www.nasdaq.com/press-release/aravive-reports-third-quarter-2021-financial-results-and-provides-corporate-updates
https://www.nasdaq.com/press-release/aravive-to-present-new-preliminary-data-from-phase-1b-trial-evaluating-avb-500-in
https://www.nasdaq.com/press-release/aravive-to-participate-in-fireside-chat-at-cantor-fitzgerald-virtual-global
https://www.nasdaq.com/press-release/aravive-to-participate-in-fireside-chat-at-h.c.-wainwright-23rd-annual-global
https://www.nasdaq.com/press-release/aravive-announces-first-patient-dosed-in-phase-1b-2-clinical-trial-of-avb-500-for-the
https://www.nasdaq.com/press-release/aravive-reports-second-quarter-2021-financial-results-and-provides-corporate-updates
https://www.nasdaq.com/press-release/aravive-to-participate-in-fireside-chat-at-2021-btig-biotechnology-conference-2021-07
https://www.nasdaq.com/press-release/aravive-achieves-second-development-milestone-from-3d-medicines-2021-07-15
https://www.nasdaq.com/press-release/aravive-to-participate-in-fireside-chat-at-2021-william-blair-biotech-focus
https://www.nasdaq.com/press-release/aravive-announces-positive-initial-results-from-phase-1b-portion-of-the-phase1b-2
https://www.nasdaq.com/press-release/aravive-announces-three-new-appointments-to-its-board-of-directors-2021-05-18
https://www.nasdaq.com/press-release/aravive-reports-first-quarter-2021-financial-results-and-announces-plans-to
https://www.nasdaq.com/press-release/aravive-announces-first-patient-dosed-in-phase-3-registrational-trial-evaluating-avb
https://www.nasdaq.com/press-release/aravive-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aravive-to-present-phase-1b-data-evaluating-avb-500-in-platinum-resistant-ovarian
https://www.nasdaq.com/press-release/aravive-announces-first-patient-dosed-in-phase-1b-2-clinical-trial-of-avb-500-in
https://www.nasdaq.com/press-release/aravive-to-participate-in-upcoming-virtual-investor-conferences-in-march-2021-03-02
https://www.nasdaq.com/press-release/aravive-announces-%2421.0-million-registered-direct-offering-with-eshelman-ventures-llc
https://www.nasdaq.com/press-release/aravive-to-present-at-the-h.c.-wainwright-virtual-bioconnect-conference-2021-01-04
https://www.nasdaq.com/press-release/aravive-announces-board-member-transition-to-advisory-role-2020-12-31
https://www.nasdaq.com/press-release/aravive-announces-phase-3-trial-design-for-avb-500-in-platinum-resistant-ovarian
https://www.nasdaq.com/press-release/aravive-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference
https://www.nasdaq.com/press-release/aravive-to-host-virtual-expert-event-focused-on-ovarian-and-renal-cancer-on-november
https://www.nasdaq.com/press-release/aravive-and-3d-medicines-announce-strategic-collaboration-to-develop-and
https://www.nasdaq.com/press-release/aravive-reports-third-quarter-2020-financial-results-and-provides-corporate-updates
https://www.nasdaq.com/press-release/aravive-appoints-michael-w.-rogers-to-board-of-directors-2020-09-17
https://www.nasdaq.com/press-release/aravive-appoints-reshma-rangwala-m.d.-ph.d.-as-chief-medical-officer-2020-09-15
https://www.nasdaq.com/press-release/aravive-to-participate-in-upcoming-virtual-investor-conferences-in-september-2020-09
https://www.nasdaq.com/press-release/aravive-strengthens-leadership-team-with-appointment-of-key-industry-veterans-2020-08
https://www.nasdaq.com/press-release/aravive-reports-second-quarter-2020-financial-results-and-provides-recent-corporate
https://www.nasdaq.com/press-release/aravive-to-participate-in-upcoming-virtual-investor-conferences-in-august-2020-07-30
https://www.nasdaq.com/press-release/aravive-announces-successful-completion-of-phase-1b-trial-evaluating-avb-500-in
https://www.nasdaq.com/press-release/aravive-added-to-the-russell-2000r-and-russell-3000r-indexes-2020-06-30
https://www.nasdaq.com/press-release/aravive-to-present-at-the-2020-rbc-capital-markets-global-healthcare-conference-2020
https://www.nasdaq.com/press-release/aravive-reports-first-quarter-2020-financial-results-and-provides-recent-corporate
https://www.nasdaq.com/press-release/aravive-and-wuxi-biologics-form-strategic-collaboration-to-develop-novel-high
https://www.nasdaq.com/press-release/aravive-announces-board-composition-and-executive-management-transitions-2020-04-09
https://www.nasdaq.com/press-release/aravive-announces-avb-500-improves-anti-tumor-effects-when-combined-with-anti
https://www.nasdaq.com/press-release/aravive-reports-fourth-quarter-and-twelve-months-ended-december-31-2019-financial
https://www.nasdaq.com/press-release/aravive-announces-initiation-of-investigator-sponsored-phase-1-2-study-of-avb-500-in
https://www.nasdaq.com/press-release/aravive-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-2020
https://www.nasdaq.com/press-release/aravive-announces-dose-escalation-of-avb-500-in-recurrent-platinum-resistant-ovarian
https://www.nasdaq.com/press-release/aravive-receives-ind-clearance-for-phase-1b-phase-2-clinical-trial-of-avb-500-in
https://www.nasdaq.com/press-release/aravive-announces-management-changes-2020-01-09
https://www.nasdaq.com/press-release/aravive-initiates-a-phase-2a-clinical-trial-of-avb-500-in-patients-with-kidney
https://www.nasdaq.com/press-release/aravive-announces-participation-at-the-2019-piper-jaffray-healthcare-conference-2019
https://www.nasdaq.com/press-release/aravive-announces-pricing-of-public-offering-of-common-stock-2019-11-27
https://www.nasdaq.com/press-release/aravive-announces-proposed-public-offering-of-common-stock-2019-11-26
https://www.nasdaq.com/press-release/aravive-reports-positive-data-supporting-relationship-between-avb-500-levels-anti
https://www.nasdaq.com/press-release/aravive-and-astrazeneca-announce-initiation-of-randomized-phase-1-2-study-of-avb-500
https://www.nasdaq.com/press-release/aravive-reports-third-quarter-2019-financial-results-and-provides-recent-corporate
https://www.nasdaq.com/press-release/aravive-announces-publication-of-avb-500-nonclinical-study-in-treatment-resistant
